China In Vitro Diagnostics(IVD) – Opportunity Assessment, Competitive Landscape and Market Forecasts to 2021

     

 The following market research report is for the ever-changing, ever-evolving In Vitro Diagnostics(IVD) market in China. The current report is the most updated report you will find on the China In Vitro Diagnostics(IVD) market. Using 2020 and preceding years as the base, the report carries accurate data on the forecasts from the year 2020 to 2025. From current statistics, facts and figures of the industry to the future prospects, business strategies and revenue of the biggest operators in the industry, you will find all the data that’s been thoroughly cross-checked and verified by the finest authors and researchers. Keyplayers and more - all the biggest companies operating in the China In Vitro Diagnostics(IVD) market have been profiled and analyzed in the report as well.

The in–vitro diagnostics(IVD) market in China has been growing rapidly in the past few years and is expected to grow steadily in the next few years, with major growth potential in segments such as infectious disease testing, chronic disease testing and diagnosis in early stages of disease. Some of the major factors driving the growth of this market are the rising incidences of chronic lifestyle diseases, public health awareness, growing aging population, demand of tests in rural areas stimulated by the healthcare reform plan, increasing demand from the middle class for high–end products and an increase in the number of private hospitals and independent testing laboratories. However, low reimbursement rate, absence of quality products by the local companies, population factors and foreign companies faces difficulty to enter the low end IVD products market are restraining the growth of this market.

Long–term Outlook: The China In Vitro Diagnostics Market is expected to reach more than US$ 10 Billion by 2021 with strong double digit growth rate from 2016 to 2021.

China IVD Market: Segment wise Outlook 

Immunoassay has emerged as a significant rapidly growing market segment in China IVD market. Immunoassay test controls nearly XX% market share by the year 2021. Other segments such as Clinical Chemistry, Molecular testing and POCT are poised to be remarkable expansion in the near future. Growing demand for infectious disease testing, chronic disease testing and diagnosis in early stages of disease will usher the China IVD market.

China IVD Market: Companies wise Outlook 

Roche is the leading company with more than XX% market share in the China IVD market and is expected to hold its strong position in the market. Sysmex Corporation and Abbott Laboratories are the other top two players in the China IVD market. Mindray and Shanghai Kehua Bioengineering(KHB) are another major participant in this market with a good hold in clinical chemistry, immunoassay and molecular testing segments providing varieties of reagents nationwide and semi–auto and automatic biochemistry analyzers to low and mid–end market users.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market, market segments, company wise sales analysis, regulation, major distributors and laboratories of IVD and outlook of the Chinese IVD companies. 

This report titled “China In Vitro Diagnostics(IVD) – Opportunity Assessment, Competitive Landscape and Market Forecasts to 2021” has been analyzed from 10 viewpoints:

1. Market and Forecast (2010 – 2021)
2. Segment Wise Market and Forecast (2010 – 2021)
3. Company Wise IVD Sales and Forecast (2010 – 2021)
4. Regulation and its Latest Development
5. Future Prospects in Attractive In Vitro Diagnostics Segments
6. Regional Trends and Opportunities
7. Main Participants/Contributors
8. Major IVD Product Companies Outlook
9. Major Private Clinical Labs and Diagnostic Services Companies Outlook
10. Market Growth Drivers and Challenges

The following segments of the China In Vitro Diagnostics market are detailed with size and six year forecast.

Clinical Chemistry
Immunoassay
Molecular Testing
Self–Monitoring of Blood Glucose (SMBG)
Point of Care Testing (POCT)
Hematology
Coagulation
Microbiology

The following companies of the China In Vitro Diagnostics market are detailed with size and six year forecast

Roche Diagnostics
Abbott Laboratories
Mindray Medical International Limited
Sysmex Corporation
Shanghai Kehua Bio–Engineering Co. Ltd.
Other Companies

The following Chinese companies of the China In Vitro Diagnostics market are detailed with company overview and its product portfolio

Mindray Medical International Limited
Shanghai Fosun Pharmaceutical Group
Mingyuan Medicare
Da An Gene Co. Ltd.
Shanghai Kehua Bio–Engineering Co. Ltd.
Zhejiang D.a. Diagnostics Technology Co., Ltd
ADICON Clinical Laboratories 
Guangzhou Kingmed Diagnostics Center Co. Ltd.
Kindstar Global
BGI – Shenzhen
OriGene Technologies

The report contains qualitative analysis, quantitative analysis and even regional analysis of major markets to cover all aspects of the China In Vitro Diagnostics(IVD) market. You can use this report for investments or business strategies. Get in touch with Market Research Port today for the best price on the China In Vitro Diagnostics(IVD) market research report.